Chan Pak, Heatherly Kathy, Kupiec Thomas C, Trissel Lawrence A
Analytical Research Laboratories, Oklahoma City, Oklahoma.
Int J Pharm Compd. 2008 May-Jun;12(3):276-8.
The physical compatibility of caspofungin acetate injection with selected other drugs during simulated Y-site coadministration was evaluated by visual observation and turbidity measurement. Five-milliliter samples of caspofungin acetate 0.7 mg/mL in 0.9% sodium chloride injection were combined with 5 mL of 67 other drugs including antineoplastics,analgesics, anti-infectives, and supportive care drugs, undiluted or diluted in 0.9% sodium chloride injection or 5% dextrose injection, and with a parenteral nutrition admixture. Visual examinations were performed with the unaided eye in normal laboratory fluorescent light and with a Tyndall beam (high-intensity monodirectional light beam) to enhance visualization of small particles and low-level turbidity. The turbidity of each sample was measured as well. The sample mixtures were evaluated immediately and at 1 and 4 hours after preparation. Nineteen of the drugs tested and the parenteral nutrition admixture were incompatible with caspofungin acetate 0.7 mg/mL during the 4-hour observation period. The remaining drugs were compatible for at least 4 hours. Gross precipitation or turbidity changes visible in normal diffuse room light with the unaided eye occurred with 18 drugs and with the parenteral nutrition admixture. Microprecipitation of particulates not visible with the unaided eye occurred with cytarabine. The measured turbidity of the caspofungin acetate control solutions and the compatible test samples remained essentially unchanged throughout the observation period. In combination with caspofungin acetate, 48 drugs and a parenteral nutrition admixture were considered to be physically compatible. In contrast, 19 drugs with the parenteral nutrition admixture exhibited frank precipitation or microparticulate formation within 4 hours and should not be simultaneously administered via Y-site with caspofungin acetate.
通过视觉观察和浊度测量,评估了醋酸卡泊芬净注射液在模拟Y型接口联合给药时与其他选定药物的物理相容性。将5毫升浓度为0.7毫克/毫升的醋酸卡泊芬净氯化钠注射液样品与5毫升67种其他药物混合,这些药物包括抗肿瘤药、镇痛药抗感染药和支持性护理药物,未稀释或在氯化钠注射液或5%葡萄糖注射液中稀释,并与肠外营养混合液混合。在正常实验室荧光灯下用肉眼进行视觉检查,并使用廷德尔光束(高强度单向光束)以增强对小颗粒和低水平浑浊度的可视化。还测量了每个样品的浊度。样品混合物在制备后立即以及1小时和4小时后进行评估。在4小时观察期内,19种受试药物和肠外营养混合液与0.7毫克/毫升的醋酸卡泊芬净不相容。其余药物至少4小时内是相容的。在正常漫射室内光线下肉眼可见明显沉淀或浊度变化的有18种药物和肠外营养混合液。阿糖胞苷出现了肉眼不可见的微粒微沉淀。在整个观察期内,醋酸卡泊芬净对照溶液和相容测试样品的测量浊度基本保持不变。与醋酸卡泊芬净联合使用时,48种药物和一种肠外营养混合液被认为在物理上是相容的。相比之下,19种药物与肠外营养混合液在4小时内出现明显沉淀或微粒形成,不应通过Y型接口与醋酸卡泊芬净同时给药。